Tag: programmed death (pd)-1 non-small cell lung cancer market

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

#Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Poised To Hit $41.45 Billion By 2030 With A 8.5% CAGR#_x000D_

The programmed death (pd)-1 non-small cell lung cancer market size has experienced robust expansion in recent years. It will grow from $27.5 billion in 2025 to $29.92 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. This historical growth can be attributed to factors such as the limited availability of PD-1 inhibitors approved for NSCLC, the rising incidence of lung cancer, increased physician awareness concerning immune checkpoint therapies, the continued reliance on chemotherapy as standard care, and the early successes observed in clinical trials for pembrolizumab and nivolumab._x000D_

_x000D_

The programmed death (pd)-1 non-small cell lung cancer market is expected to show significant expansion in the upcoming years, with its size projected to reach $41.45 billion in 2030, growing at a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is fueled by the development of novel combination therapies, the expansion of biomarker-driven personalized treatment approaches, an increasing adoption of mRNA vaccine-based therapies, rising investment in immuno-oncology research, and increased governmental and private funding for cancer immunotherapy. Prominent trends anticipated in this period include a greater reliance on pd-1 monotherapy for nsclc, an increase in combination therapies utilizing chemotherapy, ctla-4 inhibitors, and vegf inhibitors, enhanced investment in targeted therapy and mrna vaccine research, the broadening of first-line and second-line treatment alternatives, and the integration of personalized medicine and biomarker testing into treatment planning._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=98998178&type=smp&name=Programmed%20Death%20%28PD%29-1%20Non-Small%20Cell%20Lung%20Cancer%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth Factors Behind Sustained Expansion#_x000D_

The market for programmed death (PD)-1 non-small cell lung cancer is anticipated to experience growth due to the increasing acceptance of personalized treatments. These treatments are medical strategies customized to an individual’s genetic profile, lifestyle, and specific disease characteristics, designed to achieve more effective and targeted outcomes. The rising demand for personalized treatments is fueled by the growing availability of genomic profiling and biomarker testing, technologies that aid in identifying specific mutations and biological markers, thereby enabling clinicians to select therapies more likely to be effective for each patient. Personalized treatments benefit programmed death (PD)-1 non-small cell lung cancer (NSCLC) by tailoring therapies based on a patient’s genetic profile, tumor characteristics, and immune response. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, compared to 6 in the year 2022. Therefore, the expanding adoption of personalized treatments is a significant driver for the growth of the programmed death (PD)-1 non-small cell lung cancer market._x000D_

_x000D_

#Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segment Analysis Spotlighting Growth Areas#_x000D_

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Type: Monotherapy, Combination Therapy_x000D_

2) By Line of Therapy: First-line Treatment, Second-line And Beyond_x000D_

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types_x000D_

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types_x000D_

_x000D_

#Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Industry Trends Fueling Future Revenue Growth#_x000D_

Leading companies operating within the programmed death (PD)-1 non-small cell lung cancer market are concentrating on performing clinical trials of innovative therapies, including monotherapy, to enhance patient outcomes. Monotherapy is defined as a treatment strategy that utilizes a single drug or therapeutic approach to address a disease or condition. For instance, in March 2025, Akeso, Inc., a China-based biopharmaceutical company, reported positive outcomes from its Phase III HARMONi-2 trial, which evaluated Ivonescimab (AK112) in conjunction with chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC). The study successfully met its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, showcasing the therapeutic potential of the dual-targeted bispecific antibody._x000D_

_x000D_

#Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Leading Companies: Who Holds The Strongest Market Presence?#_x000D_

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc. _x000D_

_x000D_

#View The Full Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Regional Analysis: Which Region Leads By Revenue?#_x000D_

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Forecast: What Market Value Is Expected By 2030?

The programmed death (PD)-1 non-small cell lung cancer market has experienced robust expansion in recent years. Projected to rise from $27.5 billion in 2025 to $29.92 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 8.8%. Several factors drove the historical period’s development, including the restricted number of PD-1 inhibitors approved for NSCLC, a rising prevalence of lung cancer, heightened physician awareness of immune checkpoint therapies, the continued reliance on chemotherapy as a standard treatment, and the early clinical trial achievements of pembrolizumab and nivolumab.

The market for programmed death (PD)-1 treatments in non-small cell lung cancer is projected to experience substantial growth over the coming years. By 2030, it is anticipated to reach a value of $41.45 billion, reflecting an 8.5% compound annual growth rate (CAGR). Growth during the forecast period is being driven by the emergence of novel combination therapies, the expansion of biomarker-guided personalized medicine, the increasing use of mRNA vaccine-based approaches, heightened investment in immuno-oncology research, and rising levels of public and private funding aimed at cancer immunotherapy. Key trends expected over this period include a greater reliance on PD-1 monotherapy for NSCLC, an uptick in combination regimens incorporating chemotherapy, CTLA-4 inhibitors, and VEGF inhibitors, increased funding for targeted therapy and mRNA vaccine development, a broadening of both first-line and second-line treatment choices, and the integration of personalized medicine along with biomarker testing into therapeutic planning.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Industry Drivers: What Is Driving Revenue Growth?

The market for programmed death (PD)-1 non-small cell lung cancer is being propelled forward by the growing uptake of personalized treatment approaches. These therapies involve medical strategies specifically designed around an individual’s genetic makeup, lifestyle factors, and unique disease traits to deliver more precise and successful results. The heightened demand for such personalized care is driven by the expanding use of genomic profiling and biomarker testing, which enable clinicians to pinpoint specific genetic mutations and biological indicators, thereby choosing treatments that are better suited to each patient. In the context of PD-1 non-small cell lung cancer (NSCLC), personalized treatments optimize therapy selection by considering a patient’s genetic profile, tumor attributes, and immune function. A notable example occurred in February 2024, when the Personalized Medicine Coalition, a US-based nonprofit, reported that the FDA had approved 16 new personalized treatments for rare diseases in 2023, compared to only six in 2022. Consequently, the rising adoption of these individualized therapies is fueling expansion in the PD-1 NSCLC market.

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmentation Trends And Revenue Drivers

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth Trends: What Is Influencing The Future Outlook?

Key players in the programmed death (PD)-1 non-small cell lung cancer market are concentrating on conducting clinical trials for cutting-edge therapies, including monotherapy, to enhance patient outcomes. Monotherapy refers to a treatment method where only one drug or therapeutic approach is used to manage a particular disease or condition. For example, in March 2025, Akeso, Inc., a biopharmaceutical firm based in China, reported favorable findings from its Phase III HARMONi-2 trial, which tested Ivonescimab (AK112) combined with chemotherapy as a first-line therapy for advanced non-small cell lung cancer (NSCLC). The study successfully achieved its primary goal by notably prolonging progression-free survival relative to pembrolizumab, underscoring the effectiveness of this dual-targeted bispecific antibody.

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Access The Complete Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Regional Analysis And Leading Geography

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Through 2030?

The programmed death (pd)-1 non-small cell lung cancer market has experienced substantial growth in recent years. This market is projected to expand from $27.5 billion in 2025 to $29.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. The expansion observed during the historical period can be attributed to several factors, including the restricted approval of pd-1 inhibitors for nsclc, the increasing prevalence of lung cancer, enhanced physician understanding of immune checkpoint therapies, the conventional reliance on chemotherapy as standard care, and the initial positive outcomes from clinical trials of pembrolizumab and nivolumab.

The programmed death (pd)-1 non-small cell lung cancer market is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $41.45 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period stems from factors such as the creation of innovative combination treatments, the broadening scope of personalized therapies guided by biomarkers, the rising uptake of mRNA vaccine-based interventions, increasing financial commitment to immuno-oncology research, and elevated government and private sector contributions to cancer immunotherapy initiatives. Key trends expected over the forecast horizon encompass a greater embrace of pd-1 monotherapy for nsclc, an increase in combination therapies incorporating chemotherapy, ctla-4 inhibitors, and vegf inhibitors, a surge in investment dedicated to targeted therapy and mrna vaccine research, the broadening of available first-line and second-line treatment choices, and the incorporation of personalized medicine alongside biomarker testing into treatment strategy development.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

Which Drivers Are Advancing The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth?

The programmed death (PD)-1 non-small cell lung cancer market is expected to grow due to the increasing adoption of personalized treatments. These medical approaches involve tailoring therapies to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The rising demand for personalized treatments is fueled by the growing availability of genomic profiling and biomarker testing, which help identify specific mutations and biological markers, allowing clinicians to select therapies more likely to be effective for each individual. Personalized treatments benefit programmed death (PD)-1 non-small cell lung cancer (NSCLC) by customizing therapies based on a patient’s genetic profile, tumor characteristics, and immune response. For instance, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022, as reported by the Personalized Medicine Coalition, a US-based non-profit organization, in February 2024. Therefore, the increasing adoption of personalized treatments is driving the growth of the programmed death (PD)-1 non-small cell lung cancer market.

What Segment Categories Are Evaluated In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Study?

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Trends Are Influencing The Future Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Leading companies in the programmed death (PD)-1 non-small cell lung cancer market are concentrating on executing clinical trials for advanced treatments, like monotherapy, to better patient outcomes. Monotherapy represents a therapeutic method that employs a single medicine or treatment to manage a disease or ailment. For example, in March 2025, Akeso, Inc., a biopharmaceutical company based in China, released encouraging data from its Phase III HARMONi-2 trial, which investigated Ivonescimab (AK112) combined with chemotherapy for the first-line management of advanced non-small cell lung cancer (NSCLC). The research fulfilled its primary goal by notably extending progression-free survival in comparison to pembrolizumab, thus emphasizing the therapeutic capability of the dual-targeted bispecific antibody.

Which Key Players Are Active In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Access The Complete Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

Which Region Accounts For The Highest Share Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company

Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Small Cell Lung Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Between 2026 And 2030?

The programmed death (pd)-1 non-small cell lung cancer market size has experienced significant expansion in recent years. This market is anticipated to increase from $27.5 billion in 2025 to $29.92 billion in 2026, registering a compound annual growth rate (CAGR) of 8.8%. Historically, the growth can be ascribed to elements such as limited pd-1 inhibitors approved for nsclc, the rising incidence of lung cancer, heightened physician awareness concerning immune checkpoint therapies, the reliance on chemotherapy as standard care, and the initial clinical trial successes of pembrolizumab and nivolumab.

The programmed death (pd)-1 non-small cell lung cancer market size is anticipated to experience robust growth in the coming years. It is projected to expand to $41.45 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is attributable to the development of novel combination therapies, the broadening of biomarker-driven personalized treatments, increased adoption of mRNA vaccine-based therapies, rising investment in immuno-oncology research, and greater government and private funding for cancer immunotherapy. Prominent trends expected in this period include an increased uptake of pd-1 monotherapy for nsclc, an expansion of combination therapies involving chemotherapy, ctla-4 inhibitors, and vegf inhibitors, increased investment in targeted therapy and mrna vaccine research, an extension of first-line and second-line treatment options, and the integration of personalized medicine along with biomarker testing into treatment planning.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

Which Important Drivers Are Guiding The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth?

The increasing integration of personalized treatments is anticipated to drive forward the growth of the programmed death (PD)-1 non-small cell lung cancer market. These treatments are medical approaches specifically tailored to an individual’s genetic profile, lifestyle, and distinct disease characteristics to achieve more effective and targeted outcomes. The escalating demand for personalized treatments stems from the wider availability of genomic profiling and biomarker testing. These technologies are instrumental in identifying specific mutations and biological markers, thereby enabling clinicians to select therapies that are more likely to be efficacious for each patient. Personalized treatments benefit programmed death (PD)-1 non-small cell lung cancer (NSCLC) by customizing therapies based on a patient’s genetic profile, tumor attributes, and immune response. For instance, in February 2024, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, significantly more than the 6 approved in the year 2022, according to the Personalized Medicine Coalition, a US-based non-profit organization. Thus, the rising adoption of personalized treatments is a primary factor fueling the expansion of the programmed death (PD)-1 non-small cell lung cancer market.

Which Segment Types Are Examined In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segment Study?

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

Which Trends Are Contributing To Changes In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Leading firms within the programmed death (PD)-1 non-small cell lung cancer market are prioritizing clinical investigations into novel treatments, including monotherapy, aimed at enhancing patient results. Monotherapy involves employing a singular medication or therapeutic method to address an illness or ailment. As an illustration, Akeso, Inc., a biopharmaceutical firm based in China, revealed favorable findings in March 2025 from its Phase III HARMONi-2 trial, which assessed Ivonescimab (AK112) alongside chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC). This investigation achieved its main objective by considerably prolonging progression-free survival in contrast to pembrolizumab, underscoring the therapeutic promise of the dual-targeted bispecific antibody.

Which Players Are Part Of The Competitive Landscape Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Get The Full Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

Which Region Leads The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In Overall Market Size?

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company

Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Small Cell Lung Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Evolve From 2026 To 2030?

The market for programmed death (pd)-1 non-small cell lung cancer therapies has experienced robust expansion over recent years. This market is projected to expand from $27.5 billion in 2025 to reach $29.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this historical growth include the initial limited approval of PD-1 inhibitors for NSCLC, the rising incidence of lung cancer, heightened physician understanding of immune checkpoint therapies, the historical reliance on chemotherapy as standard treatment, and the promising early clinical trial outcomes for pembrolizumab and nivolumab.

The market for programmed death (pd)-1 non-small cell lung cancer is projected to experience robust expansion in the coming years. This market is anticipated to reach a valuation of $41.45 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth during the forecast period include the introduction of innovative combination therapies, the broader application of personalized treatments guided by biomarkers, the increased uptake of mRNA vaccine-based therapeutic approaches, greater investment in immuno-oncology research, and an increase in both government and private funding directed towards cancer immunotherapy. Key trends foreseen over the forecast period encompass a greater reliance on pd-1 monotherapy for nsclc, an increase in combination treatments incorporating chemotherapy, CTLA-4 inhibitors, and VEGF inhibitors, a surge in investment dedicated to targeted therapy and mRNA vaccine research, the broadening of first-line and second-line treatment choices, and the incorporation of personalized medicine with biomarker testing into treatment strategy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The programmed death (PD)-1 non-small cell lung cancer market is anticipated to expand due to the rising embrace of personalized treatments. These medical approaches are customized to an individual’s genetic profile, lifestyle, and specific disease characteristics, aiming for more effective and targeted outcomes. The growing availability of genomic profiling and biomarker testing is fueling this demand, as these technologies enable the identification of specific mutations and biological indicators, thereby assisting clinicians in choosing the most effective therapies for individual patients. Specifically for programmed death (PD)-1 non-small cell lung cancer (NSCLC), personalized treatments aid by adapting therapies according to a patient’s genetic profile, tumor attributes, and immune system response. For instance, in February 2024, data from the US-based non-profit Personalized Medicine Coalition revealed that the US Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for rare diseases in 2023, a significant rise from 6 in 2022. Consequently, the increased adoption of personalized treatments is a key factor propelling the expansion of the programmed death (PD)-1 non-small cell lung cancer market.

Which Segment Areas Are Covered In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Analysis?

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Key Developments And Trends Are Impacting The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating within the programmed death (PD)-1 non-small cell lung cancer market are concentrating on conducting clinical trials for innovative therapies, including monotherapy, to enhance patient outcomes. Monotherapy is a treatment approach that employs a single drug or therapy to address a disease or medical condition. For instance, in March 2025, Akeso, Inc., a biopharmaceutical company headquartered in China, announced positive results from its Phase III HARMONi-2 trial, which assessed Ivonescimab (AK112) combined with chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC). The study achieved its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, thereby highlighting the therapeutic potential of this dual-targeted bispecific antibody.

Which Global Companies Are Actively Competing In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Read the full programmed death (pd)-1 non-small cell lung cancer market report here:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

What Are The Leading Geographic Regions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp

Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company

Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Small Cell Lung Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Evolve From 2026 To 2030?

The market for programmed death (pd)-1 non-small cell lung cancer therapies has experienced robust expansion over recent years. This market is projected to expand from $27.5 billion in 2025 to reach $29.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this historical growth include the initial limited approval of PD-1 inhibitors for NSCLC, the rising incidence of lung cancer, heightened physician understanding of immune checkpoint therapies, the historical reliance on chemotherapy as standard treatment, and the promising early clinical trial outcomes for pembrolizumab and nivolumab.

The market for programmed death (pd)-1 non-small cell lung cancer is projected to experience robust expansion in the coming years. This market is anticipated to reach a valuation of $41.45 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth during the forecast period include the introduction of innovative combination therapies, the broader application of personalized treatments guided by biomarkers, the increased uptake of mRNA vaccine-based therapeutic approaches, greater investment in immuno-oncology research, and an increase in both government and private funding directed towards cancer immunotherapy. Key trends foreseen over the forecast period encompass a greater reliance on pd-1 monotherapy for nsclc, an increase in combination treatments incorporating chemotherapy, CTLA-4 inhibitors, and VEGF inhibitors, a surge in investment dedicated to targeted therapy and mRNA vaccine research, the broadening of first-line and second-line treatment choices, and the incorporation of personalized medicine with biomarker testing into treatment strategy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The programmed death (PD)-1 non-small cell lung cancer market is anticipated to expand due to the rising embrace of personalized treatments. These medical approaches are customized to an individual’s genetic profile, lifestyle, and specific disease characteristics, aiming for more effective and targeted outcomes. The growing availability of genomic profiling and biomarker testing is fueling this demand, as these technologies enable the identification of specific mutations and biological indicators, thereby assisting clinicians in choosing the most effective therapies for individual patients. Specifically for programmed death (PD)-1 non-small cell lung cancer (NSCLC), personalized treatments aid by adapting therapies according to a patient’s genetic profile, tumor attributes, and immune system response. For instance, in February 2024, data from the US-based non-profit Personalized Medicine Coalition revealed that the US Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for rare diseases in 2023, a significant rise from 6 in 2022. Consequently, the increased adoption of personalized treatments is a key factor propelling the expansion of the programmed death (PD)-1 non-small cell lung cancer market.

Which Segment Areas Are Covered In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Analysis?

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Key Developments And Trends Are Impacting The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating within the programmed death (PD)-1 non-small cell lung cancer market are concentrating on conducting clinical trials for innovative therapies, including monotherapy, to enhance patient outcomes. Monotherapy is a treatment approach that employs a single drug or therapy to address a disease or medical condition. For instance, in March 2025, Akeso, Inc., a biopharmaceutical company headquartered in China, announced positive results from its Phase III HARMONi-2 trial, which assessed Ivonescimab (AK112) combined with chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC). The study achieved its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, thereby highlighting the therapeutic potential of this dual-targeted bispecific antibody.

Which Global Companies Are Actively Competing In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Read the full programmed death (pd)-1 non-small cell lung cancer market report here:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

What Are The Leading Geographic Regions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp

Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company

Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Small Cell Lung Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Evolve From 2026 To 2030?

The market for programmed death (pd)-1 non-small cell lung cancer therapies has experienced robust expansion over recent years. This market is projected to expand from $27.5 billion in 2025 to reach $29.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this historical growth include the initial limited approval of PD-1 inhibitors for NSCLC, the rising incidence of lung cancer, heightened physician understanding of immune checkpoint therapies, the historical reliance on chemotherapy as standard treatment, and the promising early clinical trial outcomes for pembrolizumab and nivolumab.

The market for programmed death (pd)-1 non-small cell lung cancer is projected to experience robust expansion in the coming years. This market is anticipated to reach a valuation of $41.45 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth during the forecast period include the introduction of innovative combination therapies, the broader application of personalized treatments guided by biomarkers, the increased uptake of mRNA vaccine-based therapeutic approaches, greater investment in immuno-oncology research, and an increase in both government and private funding directed towards cancer immunotherapy. Key trends foreseen over the forecast period encompass a greater reliance on pd-1 monotherapy for nsclc, an increase in combination treatments incorporating chemotherapy, CTLA-4 inhibitors, and VEGF inhibitors, a surge in investment dedicated to targeted therapy and mRNA vaccine research, the broadening of first-line and second-line treatment choices, and the incorporation of personalized medicine with biomarker testing into treatment strategy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The programmed death (PD)-1 non-small cell lung cancer market is anticipated to expand due to the rising embrace of personalized treatments. These medical approaches are customized to an individual’s genetic profile, lifestyle, and specific disease characteristics, aiming for more effective and targeted outcomes. The growing availability of genomic profiling and biomarker testing is fueling this demand, as these technologies enable the identification of specific mutations and biological indicators, thereby assisting clinicians in choosing the most effective therapies for individual patients. Specifically for programmed death (PD)-1 non-small cell lung cancer (NSCLC), personalized treatments aid by adapting therapies according to a patient’s genetic profile, tumor attributes, and immune system response. For instance, in February 2024, data from the US-based non-profit Personalized Medicine Coalition revealed that the US Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for rare diseases in 2023, a significant rise from 6 in 2022. Consequently, the increased adoption of personalized treatments is a key factor propelling the expansion of the programmed death (PD)-1 non-small cell lung cancer market.

Which Segment Areas Are Covered In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Analysis?

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Key Developments And Trends Are Impacting The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating within the programmed death (PD)-1 non-small cell lung cancer market are concentrating on conducting clinical trials for innovative therapies, including monotherapy, to enhance patient outcomes. Monotherapy is a treatment approach that employs a single drug or therapy to address a disease or medical condition. For instance, in March 2025, Akeso, Inc., a biopharmaceutical company headquartered in China, announced positive results from its Phase III HARMONi-2 trial, which assessed Ivonescimab (AK112) combined with chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC). The study achieved its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, thereby highlighting the therapeutic potential of this dual-targeted bispecific antibody.

Which Global Companies Are Actively Competing In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Read the full programmed death (pd)-1 non-small cell lung cancer market report here:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

What Are The Leading Geographic Regions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp

Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company

Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Small Cell Lung Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the programmed death (pd)-1 non-small cell lung cancer market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market expected to grow between 2026 and 2030?

The market size for programmed death (pd)-1 non-small cell lung cancer has demonstrated strong growth in recent years. It is projected to expand from $27.5 billion in 2025 to $29.92 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. This historical growth can be attributed to various factors, including the limited number of pd-1 inhibitors approved for nsclc, the increasing incidence of lung cancer, growing physician awareness concerning immune checkpoint therapies, the reliance on chemotherapy as standard care, and the early clinical trial successes of pembrolizumab and nivolumab.

The programmed death (pd)-1 non-small cell lung cancer market size is projected for significant expansion in the next few years, forecast to reach $41.45 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is attributed to the creation of novel combination therapies, the broader application of biomarker-driven personalized treatment, increasing adoption of mRNA vaccine-based therapies, growing investment in immuno-oncology research, and rising government and private funding for cancer immunotherapy. Major trends anticipated in this period include an increased uptake of pd-1 monotherapy for NSCLC, a rise in combination therapies utilizing chemotherapy, CTLA-4 inhibitors, and VEGF inhibitors, augmented investment in targeted therapy and mRNA vaccine research, the expansion of both first-line and second-line treatment options, and the integration of personalized medicine and biomarker testing into treatment planning.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

Which Drivers Are Influencing Market Acceleration In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The programmed death (PD)-1 non-small cell lung cancer market is anticipated to expand due to the growing acceptance of personalized treatments. These treatments involve medical strategies customized to an individual’s unique genetic makeup, way of life, and specific disease characteristics, aiming for more precise and impactful results. The increased demand for personalized treatments stems from the wider accessibility of genomic profiling and biomarker testing, as these technologies facilitate the identification of particular mutations and biological indicators, enabling healthcare professionals to choose therapies with a higher probability of success for individual patients. For programmed death (PD)-1 non-small cell lung cancer (NSCLC), personalized treatments are beneficial as they customize therapies according to a patient’s genetic profile, tumor features, and immune system reaction. As an example, the Personalized Medicine Coalition, a US-based non-profit organization, reported in February 2024 that the US Food and Drug Administration (FDA) sanctioned 16 new personalized treatments for rare diseases in 2023, an increase from 6 in 2022. Consequently, the expanding embrace of personalized treatments is a key factor boosting the programmed death (PD)-1 non-small cell lung cancer market.

What Segments Are Identified Within The Structure Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Upcoming Trends Are Likely To Define The Future Path Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies in the programmed death (PD)-1 non-small cell lung cancer market are focusing on conducting clinical trials for innovative therapies, such as monotherapy, to improve patient outcomes. Monotherapy is a treatment strategy that employs a single drug or therapy to address a disease or condition. For example, in March 2025, Akeso, Inc., a China-based biopharmaceutical company, announced positive results from its Phase III HARMONi-2 trial, which evaluated Ivonescimab (AK112) in combination with chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC). The study successfully met its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, highlighting the therapeutic potential of the dual-targeted bispecific antibody.

Which Major Firms Are Strengthening Their Position In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp

Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company

Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Small Cell Lung Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Size Likely To Evolve From 2025 Through 2034?

The programmed death (PD)-1 non-small cell lung cancer market size has experienced substantial growth in recent years. It is projected to expand from $25.23 billion in 2024 to $27.50 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.0%. The growth observed in the historic period can be attributed to the increasing prevalence of non-small cell lung cancer, rising adoption of immunotherapy in developed nations, growing awareness about cancer screening, increasing approvals for monoclonal antibodies, and rising healthcare expenditure.

The market size for programmed death (PD)-1 non-small cell lung cancer is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $38.26 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the forecast period include greater investments in infrastructure dedicated to cancer treatment, improved patient accessibility to biologics within developing markets, an expanding global elderly population, enhanced reimbursement provisions for immunotherapies, and a rise in the clinical efficacy of PD-1 inhibitors. Key trends anticipated for the forecast period encompass technological progress in biomarker assessments, the evolution of combination immunotherapy approaches, significant spending on individualized treatment plans, continued research and development into new PD-1 inhibitors, and pioneering efforts in immune checkpoint blockade mechanisms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

What Are The Main Drivers Boosting The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Industry’s Expansion?

The programmed death (PD)-1 non-small cell lung cancer market is anticipated to expand due to the growing acceptance of personalized treatments. These treatments involve medical strategies customized to a person’s unique genetic makeup, way of life, and particular disease features, aiming for more precise and impactful results. The escalating need for personalized therapies stems from the wider accessibility of genomic profiling and biomarker testing, technologies that facilitate the identification of specific mutations and biological indicators, thereby enabling healthcare professionals to choose treatments more effective for individual patients. In the context of programmed death (PD)-1 non-small cell lung cancer (NSCLC), personalized treatments are beneficial as they customize therapies according to a patient’s genetic profile, tumor attributes, and immune system response. An example illustrates this trend: in February 2024, the US Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for rare conditions in 2023, an increase from 6 in 2022, as reported by the US-based non-profit, Personalized Medicine Coalition. Consequently, the expanding use of personalized treatments is propelling the growth of the programmed death (PD)-1 non-small cell lung cancer market.

What Are The Primary Types Of Segments Analyzed In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

Which Competitive Trends Are Defining The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Structure?

Major companies within the programmed death (PD)-1 non-small cell lung cancer market are concentrating on performing clinical trials for innovative treatments, such as monotherapy, with the goal of improving patient outcomes. Monotherapy refers to a treatment strategy that employs a single medication or therapeutic method to address a disease or condition. For example, in March 2025, Akeso, Inc., a biopharmaceutical firm based in China, reported promising findings from its Phase III HARMONi-2 trial, which evaluated Ivonescimab (AK112) combined with chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC). This study successfully achieved its primary objective by notably extending progression-free survival when compared to pembrolizumab, thereby emphasizing the therapeutic capability of the dual-targeted bispecific antibody.

Who Are The Prominent Global Companies Shaping The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

How Do Regional Market Performances Compare Within The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Industry?

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp

Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2025, By The Business Research Company

Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Non Small Cell Lung Cancer Nsclc Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Industry?

The market size of programmed death (PD)-1 non-small cell lung cancer has seen substantial growth in the past and it’s projected to continue on this upward trajectory. Starting at $25.23 billion in 2024, the market is expected to expand to $27.50 billion in 2025, representing a compound annual growth rate (CAGR) of 9.0%. The historic growth can be linked to a number of factors including an increase in non-small cell lung cancer cases, the growing use of immunotherapy in developed countries, increased public awareness regarding cancer screening, more approvals being granted for monoclonal antibodies, and the continued increase in healthcare spending.

The market size for programmed death (PD)-1 non-small cell lung cancer is projected to grow robustly in the forthcoming years, reaching $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. This anticipated growth during the projection period is linked to the escalating investments in cancer-dedicated infrastructure, the broadening of patient access to biological therapies in developing markets, the growth of the global aging population, the increasing financial backing for immunotherapies, and the rising success rates of clinical trials of PD-1 inhibitors. Expected trends during this same forecast period involve advancements in biomarker testing technology, improvements in combined immunotherapy protocols, funding in personalized treatment approaches, R&D for new PD-1 inhibitors, and innovative practices in immune checkpoint blockade mechanisms.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

#Which Factors Are Currently Driving The Growth Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The escalation in the use of customized therapies is predicted to fuel the growth of the programmed death (PD)-1 non-small cell lung cancer market. Customized therapies are medical strategies specifically designed to match a person’s genetic makeup, lifestyle, and acute disease features to achieve superior targeted results. The swelling demand for these treatments comes in the wake of expanded access to genomic profiling and biomarker testing. These innovative methods help in the identification of specific mutations and biomarkers, enabling medical professionals to choose therapies that are more apt to be effective for each person. These tailored treatments aid programmed death (PD)-1 non-small cell lung cancer (NSCLC) by adjusting therapies based on a patient’s genetic makeup, tumor specifics, and immune reaction. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US, declared that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, a substantial increase from the 6 approved in 2022. Hence, the escalating use of personalized therapies is fueling the growth of the programmed death (PD)-1 non-small cell lung cancer sector.

How Is The Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Structured In Terms Of Segments?

The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –

1) By Drug Type: Monotherapy, Combination Therapy

2) By Line of Therapy: First-line Treatment, Second-line And Beyond

3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types

2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Upcoming Trends Are Expected To Impact The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Globally?

Leading organizations in the market for programmed death (PD)-1 non-small cell lung cancer are placing their efforts on executing clinical experiments of innovative treatments like monotherapy to enhance patient results. Monotherapy is a therapeutic approach that employs a single drug or treatment for a disease or condition. For example, Akeso, Inc., a biopharmaceutical firm based in China, revealed successful outcomes from its Phase III HARMONi-2 trial testing Ivonescimab (AK112) coupled with chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC) in March 2025. The trial reached its main objective by prominently extending progression-free survival compared to pembrolizumab, underscoring the therapeutic potential of the dual-targeted bispecific antibody.

Who Are The Main Participants Shaping The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Landscape?

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

Which Region Currently Holds The Largest Share In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model